Abstracts tagged "Autoantibodies and scleroderma"

Abstract Number: 945 • 2017 ACR/ARHP Annual Meeting
Autoantibodies to the hPOP1 and Rpp25/38 Components of the Th/to Complex Identify a Subgroup of Systemic Sclerosis (SSc) Associated Interstitial Lung Disease (ILD) and Antibodies to hPOP1 Are Associated with Reduced Survival
Jennifer G Walker¹, Mandana Nikpour², Molla Huq³, Karen Patterson¹, Peter Roberts-Thomson⁴, Susanna Proudman⁵, Wendy Stevens⁶, Susan Lester⁷, Maureen Rischmueller⁸, Jane Zochling⁹, Joanne Sahhar¹⁰, Peter Nash¹¹, Janet Roddy¹², Catherine Hill¹³, Marie Hudson¹⁴, Murray Baron¹⁵, Janet E. Pope¹⁶, Maureen D. Mayes¹⁷, Shervin Assassi¹⁸, Michael Mahler¹⁹ and Marvin J. Fritzler²⁰, ¹Flinders University of South Australia, Adelaide, Australia, ²Melbourne University, Melbourne, Australia, ³Department of Medicine (Rheumatology), Melbourne University, Melbourne, Australia, ⁴Immunology, Flinders University of South Australia, Adelaide, Australia, ⁵University of Adelaide, Adelaide, Australia, ⁶Rheumatology, St. Vincent’s Hospital, Melbourne, Australia, ⁷Queen Elizabeth Hospital, Adelaide, Australia, ⁸Medicine, University of Adelaide, Adelaide, Australia, ⁹Menzies Institute for Medical Research, Tasmania, Hobart, Australia, ¹⁰Department of Rheumatology, Monash Medical Centre, Melbourne, Australia, ¹¹University of Queensland, Brisbane, Australia, ¹²Royal Perth Hospital, Perth, Australia, ¹³Medicine, The University of Adelaide, Adelaide, Australia, ¹⁴Division of Rheumatology, Jewish General Hospital, Lady David Institute for Medical Research, Montreal, QC, Canada, ¹⁵Medicine, McGill University, Quebec, Montreal, QC, Canada, ¹⁶Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ¹⁷Internal Medicine/Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ¹⁸University of Texas McGovern Medical School, Houston, TX, ¹⁹Research and Development, Inova Diagnostics, San Diego, CA, ²⁰Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: The clinical associations of anti-Th/To antibodies (Abs) are not fully established, and until recently immunoprecipitation (IP) was the only reliable assay. Using IP, anti-Th/To…
Abstract Number: 2687 • 2017 ACR/ARHP Annual Meeting
Characteristic of Pulmonary Arterial Hypertension in Patients with Anti-U1RNP Antibody-Positive-Connective Tissue Diseases Is Determined By the Underlying Disease Rather Than Autoantibody Profile
Hidekata Yasuoka¹, Hiroshi Takei¹, Yuichiro Shirai², Kunihiro Yamaoka¹, Masataka Kuwana^1,2 and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Patients with connective tissue diseases (CTDs) positive for anti-U1RNP antibody (U1) is characterized by overlapping feature of systemic sclerosis (SSc), systemic lupus erythematosus (SLE),…
Abstract Number: 712 • 2012 ACR/ARHP Annual Meeting
Autoantibodies to Survival of Motor Neuron (SMN) Complex Are Common in Patients with Anti-U1RNP/Sm and Are Associated with Features of Scleroderma and Myopathy
Jason YF Chan¹, Yi Li¹, Angela Ceribelli², Eric S. Sobel³, Westley H. Reeves⁴, Edward K.L. Chan² and Minoru Satoh¹, ¹Medicine, University of Florida, Gainesville, FL, ²Oral Biology, University of Florida, Gainesville, FL, ³Medicine/Div of Rheumatology, University of Florida, Gainesville, FL, ⁴Rheumatology & Clinical Imm, University of Florida, Gainesville, FL
Background/Purpose: Survival of motor neuron (SMN) complex that plays a key role in small nuclear ribonucleoproteins (snRNPs) assembly and interacts with snRNPs has recently been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].